Openbookopenbook
Equity
AnGes Inc(AMGXF)
USD --+0.00%
Reward45Moderate
Risk48Moderate
📊75%Data
Revenue growing 33% YoY
AMGXF
+0.0 · +0.00%
USD · OTCGREY
AnGes Inc | Healthcare
Profitless Growth
Market Cap:142.50M
ℹ️
Reward Rating
45
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
48
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on AMGXF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is AnGes Inc?

engages in the research and development of gene-based medicines.

AMGXF · Verdict

Moderate reward · moderate risk

AMGXF stands out on balance sheet and volatility, but watch the profitability signal.

Based on 88% data coverage

AMGXF · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet84/100

    Current ratio 1.96

  • Volatility65/100

    Above average

Watchouts 3

  • Profitability9/100

    -586% net margin · -196% ROE

  • Cash flow9/100

    -659% free-cash-flow margin

  • Valuation41/100

    Below average

Model-based scoring. For information only — not financial advice.

What is AnGes Inc?

engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. The company is listed on the OTCGREY in USA, operating in the Healthcare sector, with a market capitalisation of 142.50M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (45)

The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap142.50M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.3602
52 Week Low0.3353
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding396M
No. of Employees56
IndustryBiotechnology
ExchangeOTCGREY
Beta0.706
CurrencyUSD · Reports in JPY
Websitewww.anges.co.jp
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.